Low Body Mass Index and Low Intelligence Quotient Are Infection Risk Factors in Vagus Nerve Stimulation.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 13 03 2019
revised: 28 06 2019
accepted: 29 06 2019
pubmed: 12 7 2019
medline: 22 1 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

Risk factors for infection after vagus nerve stimulation (VNS) device implantation represent an important issue but remain unclear. We hypothesized that specific risk factors for infection would be associated with VNS device implantation. This study reviewed patients with epilepsy who underwent VNS device implantation and undertook a statistical analysis of risk factors for surgical site infection (SSI). We reviewed all medical records for patients who underwent VNS therapy in our facility between August 2011 and May 2018. Age, sex, height, body weight, body mass index (BMI), intelligence quotient (IQ), surgical incision opening time, blood loss, epilepsy classification, activities of daily living, and generator replacement were statistically compared between cases with and without SSI. We performed 208 VNS device implantation surgeries at our facility during the study period. Among these, 150 patients underwent initial implantation, 56 patients underwent first generator replacement, and 2 patients underwent second replacement. Six patients (2.7%) with initial implantation and 3 patients (5.4%) with first replacement showed SSI. Low BMI was a risk factor for infection at initial implantation (P < 0.0012) using a BMI within 1.78 kg/m This study identified low BMI and low IQ at initial implantation as risk factors for infection.

Sections du résumé

BACKGROUND BACKGROUND
Risk factors for infection after vagus nerve stimulation (VNS) device implantation represent an important issue but remain unclear. We hypothesized that specific risk factors for infection would be associated with VNS device implantation. This study reviewed patients with epilepsy who underwent VNS device implantation and undertook a statistical analysis of risk factors for surgical site infection (SSI).
METHODS METHODS
We reviewed all medical records for patients who underwent VNS therapy in our facility between August 2011 and May 2018. Age, sex, height, body weight, body mass index (BMI), intelligence quotient (IQ), surgical incision opening time, blood loss, epilepsy classification, activities of daily living, and generator replacement were statistically compared between cases with and without SSI.
RESULTS RESULTS
We performed 208 VNS device implantation surgeries at our facility during the study period. Among these, 150 patients underwent initial implantation, 56 patients underwent first generator replacement, and 2 patients underwent second replacement. Six patients (2.7%) with initial implantation and 3 patients (5.4%) with first replacement showed SSI. Low BMI was a risk factor for infection at initial implantation (P < 0.0012) using a BMI within 1.78 kg/m
CONCLUSIONS CONCLUSIONS
This study identified low BMI and low IQ at initial implantation as risk factors for infection.

Identifiants

pubmed: 31295613
pii: S1878-8750(19)31893-5
doi: 10.1016/j.wneu.2019.06.235
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e839-e845

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Naoto Kuroda (N)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Ayataka Fujimoto (A)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan. Electronic address: afujimotoscienceacademy@gmail.com.

Tohru Okanishi (T)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Keishiro Sato (K)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Shinji Itamura (S)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Shimpei Baba (S)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Mitsuyo Nishimura (M)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Naoki Ichikawa (N)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Hideo Enoki (H)

Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH